1188265-73-7

Basic information

• Product Name: benzyl 3-aminocyclobutylcarbamate
• Synonyms: benzyl 3-aminocyclobutylcarbamate;1-Piperazinecarboxylic acid, 3-(2-hydroxyethyl)-, 1,1-diMethylethyl ester;3-(2-Hydroxy-ethyl)-piperazine-1-carboxylic acid tert-butyl ester
• CAS NO: 1188265-73-7
• Molecular Formula: C12H16N2O2
• Molecular Weight: 220.26764
• Mol File: 1188265-73-7.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 352.2±22.0 °C(Predicted)
• Appearance: /
• Density: 1.067±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 15.11±0.10(Predicted)
• CAS DataBase Reference: benzyl 3-aminocyclobutylcarbamate(CAS DataBase Reference)
• NIST Chemistry Reference: benzyl 3-aminocyclobutylcarbamate(1188265-73-7)
• EPA Substance Registry System: benzyl 3-aminocyclobutylcarbamate(1188265-73-7)

Safety Data

• Hazardous Substances Data: 1188265-73-7(Hazardous Substances Data)

Usage

Description

Benzyl 3-aminocyclobutylcarbamate is a chemical compound with the formula C14H20N2O2, belonging to the carbamate class of compounds. It features a carbonyl group attached to an oxygen and a nitrogen atom, with a hydrocarbon benzyl group derived from benzene and a four-membered cyclic 3-aminocyclobutyl group containing an amino group. This unique structure and its properties render benzyl 3-aminocyclobutylcarbamate a valuable building block in the pharmaceutical industry for the synthesis of various drugs and biologically active molecules.

Uses

Used in Pharmaceutical Industry:
Benzyl 3-aminocyclobutylcarbamate is used as a precursor for the synthesis of various drugs and biologically active molecules due to its unique structure and properties, which make it a valuable building block in the development of new pharmaceutical compounds. Its potential applications include the creation of novel therapeutic agents and the enhancement of existing drug formulations.

Upstream product

• 183742-33-8 3-(methoxycarbonylmethyl)piperazine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

Structure-based design and pharmacokinetic optimization of covalent allosteric inhibitors of the mutant gtpase krasg12c

Attempts to directly drug the important oncogene KRAS have met with limited success despite numerous efforts across industry and academia. The KRASG12C mutant represents an "Achilles heel" and has recently yielded to covalent targeting with small molecules that bind the mutant cysteine and create an allosteric pocket on GDP-bound RAS, locking it in an inactive state. A weak inhibitor at this site was optimized through conformational locking of a piperazine-quinazoline motif and linker modification. Subsequent introduction of a key methyl group to the piperazine resulted in enhancements in potency, permeability, clearance, and reactivity, leading to identification of a potent KRASG12C inhibitor with high selectivity and excellent cross-species pharmacokinetic parameters and in vivo efficacy.

Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection

The invention provides novel compounds having the general formula: wherein R1, R2, R3, R4, R5, R6, X, Y, W and n are as described herein, compositions including the compounds and methods of using the compounds.

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

The present invention provides compounds of Formula Ia and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and conditions associated with excessive salt and water retention.